Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically significant improvements for patients treated with Rezdiffra in an advanced population with no approved therapies. This outcome not only highlights Rezdiffra's potential to fill a critical treatment gap in advanced MASH but also strengthens Madrigal's clinical profile as the findings were presented at the American Association for the Study of Liver Diseases annual meeting. We'll explore how this pivotal clinical trial data impacts Madrigal's investment narrative, especially given Rezdiffra's progress with difficult-to-treat cirrhosis patients. AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. Madrigal Pharmaceuticals Investment Narrative Recap To be a Madrigal Pharmaceuticals shareholder today, you need conviction in Rezdiffra's long-term, first-mover leadershi
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $568.00 to $620.00. They now have a "buy" rating on the stock.MarketBeat
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $600.00 to $650.00. They now have an "outperform" rating on the stock.MarketBeat